Esperion Therapeutics Presents Promising Test Results On Cholesterol DrugThe pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today's cholesterol-lowering statin drugs.
Esperion Starts Next Phase Of Cholesterol Drug TrialThe Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.
Esperion Gets Positive Results From New Study Of Cholesterol DrugEsperion Therapeutics Inc. Friday announced "positive" results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.
Esperion Reports Cholesterol Cut Up To 43% In Diabetics On New DrugEsperion Therapeutics' proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.